NASDAQ: AMRX · Specialty & Generic Drug Manufacturers
Amneal Pharmaceuticals (AMRX) fair value: undervalued or overvalued?
As of 3 Oct 2026, Faircurve's model values Amneal Pharmaceuticals (AMRX) at $18.90 a share. The stock last closed at $20.30, which puts the model's fair value 6.9% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 2 Oct 2026. Amneal Pharmaceuticals, Inc.
Faircurve Insights · 3 Oct 2026
Amneal Pharmaceuticals, Inc. operates alongside its various subsidiaries as a diversified pharmaceutical company. It is involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal.
Faircurve's model found a fair value of $18.90 a share on 3 Oct 2026, the midpoint of 2,000 simulations. The previous run on 26 Sep 2026 gave $18.51, a move of +2.1%. The calibrated range over 63 trading days is $15.77 to $22.91. This range is built from the fair value, as there is no live options data for the stock, and it held the price 60% of the time at this horizon, over 4,809 past valuations. The evidence grade is Medium.
The overall quality score for the business is 58 out of 100 against comparable companies. Its profitability score is 79, with ROIC at 14.5% compared to a peer median of 5.6%. Its balance sheet score is 20, with Net debt / EBITDA at 4.08x compared to a peer median of 0.84x. The model compares it with Lantheus Holdings, Inc., Elanco Animal Health Incorporated, Supernus Pharmaceuticals, Inc., and Viatris Inc. Around its last 8 earnings reports, the median size of moves, ignoring direction, was 4.3%.
Written from the figures on this page for the 3 Oct 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
What price range does the model give AMRX?
The calibrated range for AMRX over 63 trading days is $15.77 to $22.91. There is no live options data for this stock, so the range is built from the fair value and calibrated weekly against realised prices (n = 4,809 past valuations, refreshed 3 Oct 2026). Ranges built this way held the price 60% of the time at this horizon.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $13.73 to $25.17. In 42% of the simulations the fair value came out above the price the model ran on.
How does AMRX score on business quality?
Amneal Pharmaceuticals's overall quality score is 58 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 79 | 14.5%ROIC | 5.6% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 42 | 0.53xFCF / net income | 4.90x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analyst estimate revisions. | 50 | 8.0%Revenue growth, trailing | 7.5% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 53 | 0.0%Net buybacks / market value | 0.1% |
| Balance sheetNet debt to EBITDA and interest coverage. | 20 | 4.08xNet debt / EBITDA | 0.84x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 91 | 1.5 ptsEBITDA margin downside volatility, 5y | 4.4 pts |
How does AMRX compare with similar companies?
The companies in specialty & generic drug manufacturers closest to Amneal Pharmaceuticals in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| LNTH Lantheus Holdings, Inc. | $99.96 | $99.94 | 0.0% | Fairly valued |
| ALKS Alkermes plc | $41.75 | $40.97 | -1.9% | Low evidence grade |
| INDV Indivior Pharmaceuticals Inc | $35.71 | $35.86 | +0.4% | Low evidence grade |
| ELAN Elanco Animal Health Incorporated | $22.14 | $21.11 | -4.7% | Fairly valued |
| SUPN Supernus Pharmaceuticals, Inc. | $42.38 | $46.93 | +10.7% | Fairly valued |
| VTRS Viatris Inc. | $17.60 | $22.08 | +25.5% | Undervalued |
| ANIP ANI Pharmaceuticals, Inc. | $72.18 | $82.56 | +14.4% | Low evidence grade |
| PAHC Phibro Animal Health Corporation | $37.24 | $37.53 | +0.8% | Low evidence grade |
All specialty & generic drug manufacturer stocks ranked by gap to fair value
When does AMRX report earnings, and how has the stock reacted?
Amneal Pharmaceuticals's next earnings report is scheduled for 29 Oct 2026. Companies can move their dates.
Options prices on 2 Oct 2026 imply a move of about 16.3% in either direction through the nearest expiry, about 48 days out, a window that includes the report. That is the size the market is pricing, not a direction.
How AMRX moved around its last 8 earnings reports
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across these 8 reports, ignoring direction, was 4.3%.
| Report date | Two session move |
|---|---|
| 30 Jul 2026 | -4.1% |
| 7 May 2026 | -3.1% |
| 27 Feb 2026 | -5.0% |
| 30 Oct 2025 | +3.7% |
| 5 Aug 2025 | +1.1% |
| 2 May 2025 | +6.5% |
| 28 Feb 2025 | +4.5% |
| 8 Nov 2024 | +6.9% |
Amneal Pharmaceuticals at a glance
Amneal Pharmaceuticals, Inc., operating alongside its various subsidiaries, is a diversified pharmaceutical company involved in the development, acquisition of licenses, manufacturing, marketing, and distribution of both generic and specialized medicinal.
- Market value
- $6.5B
- Sector
- Healthcare
- Industry
- Specialty & Generic Drug Manufacturers
- Revenue expected, next twelve months
- $3.4B
- Consensus revenue growth, next fiscal year
- +4.5%
- Analysts with estimates
- 3
- Beta to the US market
- 0.53
- First valued by Faircurve
- 11 Jul 2026
How the fair value is worked out: the model prices Amneal Pharmaceuticals on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 26 Sep 2026 the model's fair value for AMRX was $18.51. As of 3 Oct 2026 it is $18.90, a change of +2.1%. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Amneal Pharmaceuticals's valuation
Is Amneal Pharmaceuticals stock undervalued or overvalued?
On Faircurve's model, AMRX reads as Fairly valued as of 3 Oct 2026. The model's fair value is $18.90 a share against a last close of $20.30, a gap of -6.9%.
What is AMRX's fair value?
$18.90 a share as of 3 Oct 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $13.73 to $25.17.
What price range does the model give AMRX?
$15.77 to $22.91 over 63 trading days. Ranges built this way held the price 60% of the time across 4,809 past valuations, refreshed 3 Oct 2026.
When does Amneal Pharmaceuticals report earnings next?
The next report is scheduled for 29 Oct 2026. Companies can move their dates.
How much has AMRX moved on past earnings reports?
Across its last 8 reports the median two session move was 4.3%, ignoring direction. The largest was +6.9% around the report of 8 Nov 2024.
How confident is the model in this valuation?
The model's evidence grade for AMRX is medium. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.